1140PA single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
ConclusionsIn this phase IIIb trial, nivolumab confirmed the safety and efficacy profile of the registration trial. Experiencing any grade TR AE revealed to be a favorable prognostic factor, as possible expression of effective immune response.Legal entity responsible for the studyGONO group.FundingBristol Myers-Squibb.DisclosureP. Bossi: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: Angelini; Advisory / Consultancy: MSD; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Voluntis. M.C. Merlano: Honoraria (self), consultancy or A.B.: Bristol M.S.; Honoraria (self), consultancy or A.B.: Merck S.D.; Honoraria (self), consultancy or A.B.: Merck; Shareholder / Stockholder / Stock options, Stocks: Glaxo SK; Research grant / Funding (institution), Support for clinical trials: Merck. M.G. Ghi: Honoraria (self), Advisory role: BMS; Honoraria (self), Advisory role: MSD; Honoraria (self), Advisory role: Merck Serono. G. Rinaldi: Honoraria (self), Research grant / Funding (self), Speaker and PI in clinical Trial: Novartis; Honoraria (self), Research grant / Funding (institution), Speaker and PI in clinical Trial: BMS; Research grant / Funding (self), PI in clinical Trial: MSD. F. Morelli: Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): BMS. A. Farnesi: Honoraria (self), speaker: Bayer; Honoraria (self), speaker: Novartis. D. Galizia: Honoraria (self), public speaker: BMS; Honoraria (self), congress travel costs c...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Anemia | AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Encephalitis | Grants | Head and Neck Cancer | HNSCC | Hypopharyngeal Cancer | Hypothyroidism | Italy Health | Laryngeal Cancer | Legislation | Men | Merck | Nanotechnology | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Pfizer | Pharmaceuticals | Politics | Skin Cancer | Squamous Cell Carcinoma | Teaching | Universities & Medical Training